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ABSTRACT
Aim: The aim of this study was to evaluate gastrointestinal (GI) complications after
kidney transplantation in the Finnish population with a special focus in upper
gastroduodenal ulcer development, gallstone disease and biliary complications,
pancreatitis, colon perforations and GI malignancies.
Patients: The adult patients included in these studies underwent kidney transplantation at
Helsinki University Central Hospital in Finland in 1990-2000.
Methods: Data on severe GI complications were collected from the Finnish Kidney
Transplantation Registry and patient records. Questionnaires about upper gastroduodenal
and gallstone complaints were sent to a subgroup of patients. Helicobacter pylori IgG and
IgA antibodies were measured from 500 patients before kidney transplantation and after a
median 6.8-year follow up, when also CagA antibodies were determined. For studies of
gastroduodenal cytomegalovirus (CMV) infection oesophagogastroduodenoscopy
(OEGD) with biopsies was performed on 46 kidney transplantation patients suffering
from gastroduodenal symptoms and 43 dyspeptic controls. To determine the risk of
gallstone formation after the transplantation ultrasound (US) examination of the
gallbladder was performed on 304 patients after a median of 7.4 years post
transplantation. In addition to this, data from these 304 patients were collected on serum
lipids, body mass index (BMI) and the use of statin medication.
Results: The rate of severe GI complications was 147 (10%) after 1515 kidney
transplantations, the complications occurring after a median time of 0.93 years. 6% of the
complications were fatal. More than half of the complications occurred during the first
post transplantation year, with the highest incidence in gastroduodenal ulcers and
complications of the colon. Patients with GI complications were older and had more
delayed graft function (DGF), and patients with polycystic kidney disease (PKD) had
more GI complications than the other patients. H.pylori seropositivity rate was 31% in
kidney transplantation patients, and this had no influence on graft or patient survival.
29% of the H.pylori seropositive patients seroreverted without eradication therapy. 74%
of the kidney transplantation patients had CMV specific matrix protein pp65 or CMV
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delayed early protein p52 positive findings in the gastroduodenal mucosa, and 53% of the
pp65 or p52 positive patients had gastroduodenal erosions without H.pylori findings.
After the transplantation 165 (11%) patients developed gallstones. A biliary
complication, including 3 cases of biliary peritonitis and 1 fatal cholecystitis, developed
in 15% of the patients with previous or present gallstones. 13 (0.9%) patients had
pancreatitis, 3 (23%) of these were fatal. Colon perforations, 31% of them fatal, occurred
in 16 (1%) patients. 13 (0.9%) developed a GI malignancy during the follow up.
Conclusions: Patients with gastroduodenal ulcers and colon complications were the
biggest groups of GI complications after kidney transplantation.  Most of the
complications occurred early after transplantation. H.pylori has negligible influence on
the outcome of kidney transplantation patients. On the other hand, CMV infection
explains a part of the gastroduodenal lesions in kidney transplantation patients. In this
patient group of kidney transplantation patients colon perforations are especially serious.




Kidney transplantation has been established as the most efficient treatment of end state
renal disease with the advantage for the patient to live a nearly healthy life. It is also more
cost-effective than dialysis if the kidney graft survives more than 1 to 3 years (Salonen et
al. 2003, Gaston and Gitlin 2005). The first successful human kidney transplantation was
performed between identical twins in 1954 (Merrill et al. 2001). In Finland the first
kidney transplantation was performed in 1964. Since then the number of kidney
transplantations has increased gradually. In 2005 166 adult kidney transplantations were
performed in Finland. 5 of these transplants were from living donors and 161 were
cadaveric kidney transplants. At the end of 2005 the total number of all Finnish kidney
transplantations was 4919 (The Finnish Kidney Transplantation Registry).
Several factors, such as the cause of terminal uraemia, immunosuppressive medication
and infections, can predispose kidney transplantation patients to the development of
gastrointestinal (GI) problems. The diagnosis of severe GI complications can be delayed
and treatment can be more complicated due to the use of immunosuppressive drugs
(Stelzner et al. 1997).
Systemic lupus erythrematosus (SLE) and polycystic kidney disease (PKD) predispose
patients independently to pancreatitis, diverticulosis and colon perforations (Padilla et al.
1994, Andreoni et al. 1999). Diabetes mellitus (DM) is known to predispose kidney
transplantation patients to infectious GI complications (Logan et al. 2002). Gastric ulcer
disease was a frequent and often fatal complication of kidney transplantation in the
earlier years (Ahonen et al. 1977, Owens et al. 1977). The use of immunosuppressive
medication also predisposes to the development of gallstones and pancreatitis  (Frick et
al. 1987, Fernandez-Cruz et al. 1989, Alberu et al. 2001).
Many opportunistic infections are common during immunosuppressive medication.
Cytomegalovirus (CMV), which is considered to be the most important single post
transplantation pathogen, can cause ulcerations, haemorrhage and perforations in the
entire GI tract  (Goodman et al. 1979, Goodgame 1993).
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International recommendations for evaluating both the recipient and donor have been
drawn to minimize the postoperative risks of kidney transplantation (EBPG 2000,
Kasiske et al. 2001, EBPG 2002, Kälbe et al. 2005, Knoll et al. 2005). The pre
transplantation work up in Finland includes abdominal ultrasound (US) screening and
further examination of patients with GI complaints. The treatment of symptomatic colon
diverticular disease and cholecystectomy in cases of gallstones have been among the
requisites for acceptance to  kidney transplantation.
The present study was carried out to examine the incidence and characteristics of severe
post transplantation GI complications in Finnish kidney transplantation patients and to
find out possible risk factors for these complications.
12
REVIEW OF THE LITERATURE
1.KIDNEY TRANSPLANTATION
1.1.General
Kidney transplantation is the only curative treatment for terminal uraemia. Primary renal
diseases, congenital dysplasia of the urinary tract, as well as systemic diseases affecting
kidneys, such as DM, SLE and amyloidosis, can lead to the development of end stage
renal disease (Salmela et al. 1995).
The main indications for adult kidney transplantation in Finland in 2000-2003 were DM
in 25%, PKD in 21%, glomerulonephritis in 21%, interstitial nephritis in 7% and
congenital dysplasia of the urinary tract in 4% of the patients (Salmela et al. 2004).
Kidney transplantation is not suitable for all the patients with terminal uraemia. An
absolute contraindication for kidney transplantation is an acute infection (Salmela et al.
1995, EBPG 2000). In patients with malignancy, at least a 2-year disease free time period
before the transplantation, sometimes longer, is recommended depending on the type of
cancer (EBPG 2000, Kälbe et al. 2005, Knoll et al. 2005). Relative contraindications
consist of severe cerebral and cardiopulmonary circulatory disturbances, severe
peripheral arterial disease, and severe psychiatric causes. HIV (human immunodeficiency
virus), hepatitis B and C positivities are also considered to be relative contraindications
(Kälbe et al. 2005). In contrast, old age is nowadays not considered to be a
contraindication for kidney transplantation (Kälbe et al. 2005, Fijter and Persijn 2005).
The availability of donor organs sets limits to the number of kidney transplantations. In
Finland, as well as in most of the other West European countries, the majority of the
donated kidneys are from brain dead donors and only a few  from living donors. In fact,
Finland has the lowest number of living donors in the Nordic countries (Grunnet et al.
2001). Contraindications for kidney donation are chronic renal disease, a history of
potentially metastasing malignancy, severe hypertension, sepsis, HIV positivity, hepatitis
13
B surface antigen positivity, hepatitis C, intravenous drug abuse, oliguric acute renal
failure, and prolonged warm ischaemia (EBPG 2000, Kälbe et al. 2005).
Determination of ABO blood group and tissue typing with specific, serological or DNA
based determinations of HLA (human leukocyte antigen) types are used to find the most
suitable recipient-donor combinations. It is required in Finland that the recipient and
donor share at least 2 HLA-AB and 1 HLA-DR alleles (Salmela et al. 1994, Kyllönen et
al. 1999). Finally a cross-match test is performed between the recipient’s blood and donor
lymphocytes to avoid hyper acute rejection.
1.2. Operation technique
The surgical technique in adult kidney transplantation has changed only a little during the
years (Koostra 1994). The donor kidney is transplanted extraperitoneally to the iliac
fossa.   The venous anastomosis is performed between the renal vein of the kidney and
the recipient’s external iliac vein end to side. The renal artery is connected with either
internal iliac artery end to end or with external iliac artery end to side. The urether is
anastomosed either to the recipient’s urinary bladder or, when short or if the bladder is
contracted, to the recipient’s ipsilateral urether (Oliver 1995, Singer et al. 2005). Usually
the recipient’s own kidneys are not removed during the operation.
1.3. Immunosuppressive medication
After kidney transplantation patients need permanent immunosuppressive medication to
prevent graft rejection and thereby loss of the graft.  The mechanism of all the current
immunosuppresive drugs is targeting T cell activation and cytokine production, clonal
expansion or both. Figure 1 presents the targets of the immunosuppressants used in
kidney transplantation (Denton et al. 1999).
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Figure 1. Targets for immunosuppressive agents (Reprinted from the Lancet 1999 Vol 353,
Denton M, Magee C, Sayegh M. Immunosuppressive strategies in transplantation pp.1083-1091.
Copyright with permission of Elsevier)
Calcineurin inhibitors
Calcineurin inhibitors are the cornerstones of modern immunosuppressive medication.
The introduction of cyclosporine A (CsA) to clinical use during the early 1980’s has
dramatically improved the results of kidney transplantation. Since CsA was taken in use,
acute rejection rate has fallen to 25% in Finland (Salmela and Kyllönen 1999, Kyllönen
et al. 2000a). CsA is a small polypeptide of fungal origin that can form a complex with
calcineurin inhibiting its normal function and thereby limiting cytokine production and T-
cell proliferation. Tacrolimus (FK 506), a newer product which is a macrolide antibiotic
compound isolated from streptomyces tsukubaensis, has the same mechanism of action as
CsA. Nephotoxicity is an important side effect of calcineurin inhibitors which limits their
use (Danovitch 2005). Tacrolimus seems to be less nephrotoxic than CsA (Kälbe et al.
2005). Other side effects consist of effects on lipid profile, glucose intolerance,
neurotoxic and cardiotoxic effects, thromboembolic complications and hyperuricaemia.
Tacrolimus has been shown to be associated with DM in 20% as compared to 4% of CsA
(Vincenti et al. 2002). Hypercholesterolemia, hypertriglyceridemia and effects such as
acne, hirsutism and genital hyperplasia are more common with the use of CsA (Pirsch et
al. 1997, Barry 1999).
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Antiproliferative agents
Antiproliferative agents prevent the expansion of alloactivated T and B cells.
Azathioprine (AZA) has been used since the 1960’s in clinical transplantation. It is a
purine analogue, an imidazole derivative of 6-mercaptopurine (Denton et al. 1999,
Danovitch 2005). It inhibits purine nucleotide synthesis and interferes with the synthesis
of DNA. It acts as a myelocyte suppressant and decreases the number of circulating
monocytes. The most important side effect of AZA is bone marrow suppression.
Mycophenolate Mofetil (MMF) is a prodrug, the active product of which is mycophenolic
acid, a fermentation product of several penicillum species. It blocks the proliferation of T
and B cells more specifically than AZA and inhibits antibody formation and generation
of cytotoxic T cells in vitro (The tricontinental MMF renal transplantation study group
1996). Its use is limited by the many GI side-effects (Hardinger et al. 2004). Sirolimus
(rapamycin) is a new potent immunosuppressive agent which acts by inhibiting T cell
responses to cytokines. It inhibits intracellular signalling distal to the interleukin-2
receptor. Side effects consist of hyperlipidemia and thrombocytopenia (Murghia et al.
1996).
Corticosteroids
Corticosteroids have been used in transplantation since the early 1960’s. They are non-
specific anti-inflammatory agents and act by inhibiting cytokine production in T cells and
macrophages. All stages of T-cell activation are inhibited. Corticosteroids can cause
many side effects such as osteoporosis, cosmetic changes, impaired wound healing,
impaired resistance to infection, cataract, hyperlipidemia, glucose intolerance and
psychological effects  (Danovitch 2005).
 Antibodies
Anti T-cell preparations are used both in induction therapy in hyperimmunised patients
and in steroid resistant rejections. Antithymocyte globulin (ATG) and
antilymphocyteglobulin (ALG) bind themselves to multiple antigens on lymphoid cells.
Monoclonal antibody muromonab CD3 (OKT3) is a murine monoclonal antibody in wide
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clinical use (Cosimi et al. 1981). It acts with the antigen recognition complex (CD3) on T
cells. A feared side effect of its use is the toxic cytokine release syndrome. Basiliximab
and daclizumab are new antibody preparations that act by blocking the interleukin-2
receptor expressed only by activated lymphocytes. Toxic cytokine release syndrome has
not been reported in association with their use (Barry 1999).
Combination treatment
Because of the many side effects and different targets of inhibiting T cell activation,
immunosuppressive agents are used in combination, usually as triple therapy, which
includes CsA or tacrolimus combined with AZA or MMF and methylprednisolone (MP)
(Denton 1999).
2. COMPLICATIONS OF KIDNEY TRANSPLANTATION
2.1. Technical postoperative complications
Wound infection occurs nowadays in less than 1% of the cases.  This is so, because
steroid doses are smaller than before and prophylactic antibiotics are used. Also recipient
patients are in better general health condition than before (Beyga and Kahan 1998).
Postoperative bleeding usually occurs from the small vessels in the renal hilum that are
not ligated during the operation. The bleeding can also arise from the vascular
anastomoses when a myotic aneurysm or the graft itself ruptures (Beyga and Kahan 1998,
Singer et al. 2005).
Graft thrombosis incidence varies from 0.5%-8% (Singer et al. 2005). It can be both of
arterial or venous origin. Graft thrombosis usually occurs a few days after the
transplantation.  It is usually caused by poor surgical technique or acute rejection.
Renal artery stenosis occurs usually later, some weeks or months after the
transplantation. The prevalence varies from 2%-10% (Beyga and Kahan 1998). The
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stenosis can be in the end to end suture line or be pre- or post-anastomotic. It can be
caused by rejection, arteriosclerosis, clamp injury, wrong suture technique, angulation of
the vessel, and vessel size disproportion. The stenosis can usually be repaired with
angioplasty and intra-arterial stents, and with this the recurrence rate has decreased to
10% (Bruno et al. 2003, Akbar et al. 2005). Introduction of the end to side anastomosis
with aortic cuff to the recipients’ external iliac artery has decreased the prevalence of
renal artery stenosis.
Urological complications occur in 3%-20% of the patients after kidney transplantation
(Pisani et al. 2005). In Finnish kidney transplantation patients the incidence has been
4.2% (Mäkisalo et al. 1997). The incidence of urine leakage can rise up to 10% (Beyga
and Kahan 1998). It can be caused by slack urethral reimplantation or bladder closure or
ishaemic urethral wall lesion. Urethral obstruction can be caused by a blood clot, urethral
slough, technical problems in surgery, like malrotation or kinking of the anastomosis, and
by compression from the outside by a lymphocele (Beyga and Kahan 1998).
Lymphoceles occur within weeks and the first months after the transplantation. They are
caused by a leak from severed lymphatic vessels near the iliac vessels during the
transplantation. The incidence of lymphocele formation varies between 1%-18%
(Gruessner et al. 1995). Lymphoceles occur as an abdominal mass usually located
medially to the transplanted kidney, between the graft and the bladder (Akbar et al.
2005). Lymphoceles can cause urethral obstruction and compress iliac veins leading to
oedema of the leg and, in severe cases, even to deep vein thrombosis (Gruessner et al.
1995).
2.2. Rejections
The patient’s immunosystem is activated after invasion of foreign material and both a
non-specific inflammatory process and T-cell mediated antigen specific immune
responses follow it.  Rejection can be defined as an immune response against the graft,
which without treatment leads to the destruction of the graft. There are three different
types of rejection when classified according to the time of onset (Nast and  Cohen 2005).
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Hyperacute or accelerated rejection occurs if the recipient has previously been sensitised
against the donor antigens and has circulating cytotoxic Ig (immunoglobulin) G anti-
donor HLA or anti-AB (blood group) antibodies because of previous transplantations,
blood transfusions or pregnancies. Hyperacute rejection usually occurs during the first
hours after transplantation and leads to the loss of the graft. In most cases it can be
avoided by the pre transplant cross-match test.
Acute rejection occurs usually during the first weeks or months after transplantation. If
mild rejections are included, acute rejections occur in 40%-70% of the cases (Kälbe et al.
2005). It is a specific immunoresponse against the graft and its cells, and it manifests
typically as asymptomatic elevation of serum creatinine. The diagnosis is confirmed with
a doppler US and US guided biopsy which shows infiltrates of lymphocytes and oedema.
Acute rejection usually responds well to high dose corticosteroid treatment, and it only
slightly affects long-term graft survival (Kyllönen et al. 2000a).
Chronic rejection is defined as a gradual but progressive impairment of renal allograft
function in the absence of other specific causes (Isoniemi 1994). It can occur at any time
after the first post transplantation months. The pathogenesis is not well understood. It
does not respond well to antirejection treatment and it usually leads to the loss of the
graft.
2.3. Post transplantation infections
Immunosuppressive treatment predisposes transplantation patients to increased rates of
normal and opportunistic, systemic and localized infections of viral, bacterial and fungal
origin (Helderman and Goral 2002). Figure 2 presents the occurrence of common
infections after transplantation (Fishman and Rubin 1998, American Society of
Transplantation 2004, Kubak et al. 2005).  The sources of infections occurring in the first
weeks after kidney transplantation, such as pneumonia, urinary tract infections and
wound infections, are similar to those that develop in nonimmunocompromised patients
who have undergone surgery. Infections with opportunistic pathogens and
cytomegalovirus usually develop 1 to 6 months after the transplantation, and infections
that are common in the general population can be seen after 6 months (Akbar et al. 2005).
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Cytomegalovirus (CMV) is considered to be the most common pathogen of organ
transplantation occurring in 60%-70% of organ-transplanted population. CMV infection
in a transplantation patient can be a primary CMV infection in a previously uninfected
host, reinfection by the virus, or most commonly, reactivation of the latent virus
(Goodgame 1993). CMV can affect many organs causing pneumonitis, hepatitis,
pancreatitis, retinitis and thrombocytopenia or leucopenia (Shrestra et al. 1996, Griffiths
et al. 2000, Sinha et al. 2003). CMV can cause ulcerations and haemorrhage in the whole
GI tract (Goodgame 1993). CMV colitis can be the cause of colon perforation in
transplantation patients (Goodman et al. 1979). The incidence of GI CMV disease is 10%
in transplantation patients (Meng and Smith 1999), and CMV infection usually occurs
during the first moths after transplantation (Shrestra et al. 1996).  CMV is a risk factor for
other infections both fungal and bacterial, and CMV infection is frequently found with
the reactivation of the human herpesvirus 6 and 7 (Lautenschlager 2003) which are
associated with graft rejection (Griffiths et al. 2000, American Society of Transplantation
2004).
Herpes simplex virus (HSV) is the second common viral agent causing clinical infection
after transplantation. The latent virus is usually reactivated within the first 6 weeks after
transplantation.  It is known to affect many parts of the GI tract (Helderman and Goral
2002).
Varicella zoster virus (VZV) infection causes significant morbidity among solid organ
transplant recipients. Its occurrence in kidney transplantation patients is 2%-10%.
(Gourishankar et al. 2004, American Society of Transplantation 2004). In adults the
infection is usually due to reactivation of the virus (American Society of Transplantation
2004)
Activated Ebstein Barr virus (EBV) is present in 20%-30% of transplant recipients
receiving immunosuppressive therapy and in more than 80% of patients receiving
antilymphocyte-antibody therapy (Fishman and Rubin 1998). The importance of EBV in
transplantation is its role in the pathogenesis of post transplantation lymphoproliferative
disorders (PTLDs). PTLD is usually a B-cell lymphoproliferative process. Its severity can
vary from a benign process to a highly malignant polyclonal lymphoma (Fishman and
Rubin 1998).
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   Conventional                                                                                              Community-acquired or
    Nosocomial            Unconventional or opportunistic infections                    persistent infections
     Infections
Bacterial
                          Wound infections,catheter-related infections, pneumonia
                                    Nocardia
                                   Listeria, tuberculosis
       Viral
        HSV
                               Onset of CMV                                                               CMV retinitis or colitis
                                          EBV, VZV, influenza, adenovirus
                                                                                                                    Papillomavirus, PTLD
         Onset of hepatitis B or hepatitis C
Parasitic
                                                        Strongyloides
                                                Toxoplasma
                                Leishmania
                                                       Trypanosoma cruzi
Fungal
                                  Pneumocystis
                                 Aspergillus                                     Cryptococcus
            Candida                                                     Geographically restricted, endemic fungi
      0                 1                 2                  3                 4                  5                 6
                                                 months after kidney transplantation
 Figure 2. Usual occurrence of infections after transplantation
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Fungal infections are the most fatal infections in immunosupressed patients (Meng and
Smith 1999). Candida albicans is the most common fungal pathogen in this patient group
and oesophagus the most common site of GI candida infection (Graham et al. 1995a,
Helderman and Goral 2002, American Society of Transplantation 2004). Opportunistic
fungal pathogens such as aspergillus and pneumocystis carinii (pneumocystis jiroveci)
are also present post transplantation. The incidence of pneumocystis carinii pneumonia is
5%-15% after transplantation (American Society of Transplantation 2004). After
introducing the prophylaxis of small dose sulphatrimethoprime  (trimethoprime 80mg,
sulfamethoxazole 400mg) pnemocystis carinii pneumonia has almost vanished. The
prophylaxis has also reduced the risk of common respiratory pathogens and the risk of
urinary infection in kidney transplantation patients (Fishman and Rubin 1998).
Bacterial pathogens in the early post transplantation period are similar to those of
nonimmunosuppressed patients. Bacterial infections such as listeria monocytogenes,
yersinia enterocolica and clostridium difficile can often be seen in transplantation
patients with systemic CMV infection (Helderman and Goral 2002). Clostridium difficile
infections have become more common in transplantation patients during recent years
(Schaier et al. 2004).
2.4. Gastrointestinal complications
2.4.1. Gastroduodenal ulcer disease
In studies from the 1960’s and 1970’s, before the use of modern ulcer medication, the
mortality because of ulcers in this patient group was over 40% due to massive
haemorrhage and perforation. Even pre-kidney-transplant ulcer surgery was advocated in
some centres  (Owens et al. 1977, Ahonen et al. 1977). At present the incidence has
declined mainly because of the screening of peptic ulcers pre transplant and because of
the use of modern ulcer prophylaxis with histamine receptor 2 (H2) blockers or proton
pump inhibitors (Ponticelli and Passerini 2005).  Previously it was suggested that also
dialysis treatment predisposed to the development of peptic ulcer and its complications
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(Ala-Kaila 1987), but more recent studies do not support this (Kang 1993, Ponticelli and
Passerini 2005).
The association of Helicobacter pylori infection with peptic ulcer disease is well known
(NIH 1994). For duodenal ulcers it is almost 100% (Gisbert et al. 1999).  The gene cagA
that codes for the CagA protein is present in over 60% of the H. pylori strains in western
countries (Atherton 1998, Gunn et al. 1998). In Finland that prevalence has varied
between 71% and 79% (Oksanen et al. 2000, Rautelin et al. 2000).  There is an
association of more severe disease with CagA-positive strains with atrophy and higher
incidence of duodenal ulcer (Atherton 1998, Navaglia et al. 1998). In the general
population cagA-positive H. pylori infection seems to disappear more rapidly than the
cagA-negative one (Perez-Perez et al 2002). In uraemic and kidney transplantation
patients the seroprevalence of H.pylori does not differ from that of a normal population
(Davenport et al. 1991, Gladziva et al. 1993, Özgur et al. 1997).
Viral organisms, like CMV and HSV, also cause ulcerations in the gastroduodenal tract
(Goodgame 1993, Mosimann et al. 1994, Halme et al. 1998, Toljamo et al. 2002).
Development of peptic ulcer in kidney transplantation patients is multifactorial
(Helderman and Goral 2002). In addition to the infectious agents, the stress of surgery,
the use of non steroidal anti-inflammatory drugs, the use of steroids, AZA and MMF, and
increased acid secretion during post transplantation dialysis have an influence on the
formation of gastroduodenal ulcers (Steger et al. 1990). The association between
corticosteroid treatment and ulcer development has been controversial, but recently the
risk has been considered to increase only in patients with non-steroidal anti-inflammatory
drug treatment, only used in low doses as thrombosis prophylaxis in kidney
transplantation patients (Weil et al. 2000). Corticosteroids play a more important role in
delaying the healing of the lesion after the use of non steroidal anti-inflammatory drugs
than causing de novo ulceration (Piper et al. 1991). The incidence of severe
gastroduodenal ulcers has diminished since CsA and effective ulcer prophylaxis with H2
blockers and proton pump inhibitors and new endoscopic techniques were taken in use
(Benoit et al 1993, Troppmann et al 1995, Ponticelli and Passerini 2005). Steroid
treatment can mask the symptoms and delay treatment.  In Steger et al.’s material of
kidney transplantation patients only 39% of the patients with post transplantation
23
gastroduodenal ulcers had symptoms, i.e. the number of ulcers in kidney transplantation
patients is probably underestimated (Steger et al. 1990).
2.4.2. Gallstone disease and biliary complications
The aetiology of gallstone disease is multifactorial with predisposing factors, such as
high age, female gender, family history of gallstone disease, obesity, rapid weight loss
and diabetes mellitus. Also high serum triclycerides and low HDL (high density
lipoprotein) levels appear to be risk factors for gallstone disease (Diehl 1991). In
transplantation patients increased triglyceride and cholesterol levels are associated with
the long term use of corticosteroids (Charco 2002, Kao et al. 2003). CsA, which is
metabolised in liver, is lithogenic due to increased cholestasis and reduced bile flow
(Lorber et al. 1987, Helderman and Goral 2002). Over 10% of the western population
have gallstones (Diehl 1991, Juvonen 1994). The prevalence of pretransplant gallstone
disease varies from 6.5% to 10.3% in kidney transplant recipients (Kao et al. 2003,
Moray et al. 2003, Sianesi et al.  2005). After kidney transplantation the number of
patients with newly diagnosed gallstones is 7.1%-17% (Graham et al. 1995, Greenstein et
al. 1997). The prevalence of gallstone disease for pancreas and/or kidney transplantation
patients is 16% when gallstones which are diagnosed both pre and post transplant are
included (Kao et al. 2003). Kidney transplantation patients with DM are predisposed to
the development of gallstones. The incidence of gallstone disease in kidney
transplantation patients with DM was 27.3% compared to 12.2% in patients without DM
(Lowell et al. 1993).
Studies of heart transplantation patients show that symptoms of gallstone disease develop
in transplantation patients sooner than in the general population. The onset of symptoms
is usually before the second year after transplantation (Milas et al. 1995). There is some
controversy in studies about the morbidity and mortality of gallstone disease in kidney
transplantation patients. Some studies show low incidence and morbidity of symptomatic
gallstone disease (Greenstein et al. 1997, Melvin et al. 1998), but in one study the
surgical morbidity occurred in 14% and mortality in 7% and kidney grafts were lost in
20% of the patients with symptomatic gallstones operated after the transplantation
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(Graham 1995b). In the general population with gallstones complications of untreated
gallstone disease like cholecystitis, cholangitis and biliary pancreatitis occur in 1%-2%
annually (Friedman et al. 1989, Friedman 1993). The risk of gallstone complications in
transplantation patients seems to be higher and the progression of symptoms more rapid
(Kao et al. 2003, Sianesi et al. 2005). Because of immunosuppressive therapy the
complications of gallstone disease are more severe and the diagnosis can be delayed.
2.4.3. Pancreatitis
Pancreatitis is an uncommon, but very serious and often fatal complication of kidney
transplantation (Fernandez-Cruz et al. 1989, Slakey et al. 1997). The incidence of
pancreatitis after kidney transplantation varies from 0.8%-11% (Frick et al. 1987,
Fernandez- Cruz et al. 1989, Slakey et al. 1997, Adani and Baccarani 2005).
Hyperparathyreoidism, hypercalcemia, the use of AZA and viral infections are
considered to be specific aetiological factors of post transplantation pancreatitis (Mallory
and Kern 1980, Frick et al. 1987, Fernandez-Cruz et al. 1989, Helderman and Goral
2002, Sinha et al. 2003). Frick et al. found a 5 times higher incidence of pancreatitis in
kidney transplantation patients with hyperalcemia than in the general population (Frick et
al. 1987). It has also been suggested that the use of corticosteroids can contribute to the
development of pancreatitis post transplant, although the link has not been clearly shown
(Mallory and Kern 1980, Fernandez-Cruz et al. 1989). As in general population acute
pancreatitis can also develop in kidney transplantation patients due to alcohol use and
biliary tract disease (Fernandez-Cruz et al. 1989).
2.4.4. Complications of the colon
Severe colon complications in kidney transplantation patients consist mainly of
diverticulitis and CMV colitis (Goodman et al. 1979, Dominquez Fernandez et al. 1998).
Nonobstructing colon dilatation is a more uncommon complication of kidney
transplantation (Korneru et al. 1990). Perforation of the colon is the most feared
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consequence of these complications, because the mortality rises to over 50% in this
patient group (Benoit et al. 1993). A delay in the diagnosis in these patients is common,
as the symptoms and signs are sparse and often masked by immunosuppression
(Dominquez Fernandez et al. 1998). The incidence of colon perforations is 1%-2% in
kidney transplantation patients (Church et a. 1986, Stelzner et al. 1997). Diverticulitis is
its most common cause (Dominquez Fernandez et al. 1998, Remzi 2002). Other causes
can be ischaemia or CMV colitis (Goodman et al. 1979, Remzi 2002).
Diverticulosis may occur in up to 50% of patients with uraemia (Stelzner et al. 1997).
Patients with adult PKD have a higher incidence of colon diverticular disease than others
(Scheff et al. 1980, Dominiquez Fernandez et al. 1998). Andreoni et al. showed also a
higher perforation rate of 4.8% in this patient group (Andreoni et al. 1999). Lederman et
al. found that 20% of patients with PKD had a history of acute diverticulitis compared to
3% of patients with other causes of terminal uraemia. Patients with PKD are also at a
higher risk of diverticular complications after kidney transplantation than others
(Lederman et al. 1998, Lederman et al. 2000). Stelzner at al. have found 2 different types
of colon perforation in kidney transplantation patients. The first type which is usually due
to diverticulitis or CMV colitis develops early after transplantation and is associated with
high doses of immunosuppressive medication, particularly corticosteroids. The second
type can occur years later and is caused by diverticulosis or malignancy (Stelzner et al.
1997).
2.4.5. Gastrointestinal malignancies
Long-term immunosuppression increases the risk of malignancies in kidney
transplantation patients (London et al. 1995, Bustami et al. 2004). When GI malignancies
are concerned, the risk of colon cancer is increased. In the material on transplantation
patients by the University of Michigan the standardised incidence rate for colon cancer
was significantly elevated being 2.5 (Feng et al. 2003). In a Finnish material on 2890
kidney transplantation patients the incidence of cancer was 16% after 15 years and 22%
after 20 years; 39 (17%) of these 230 malignancies were of GI origin. The standardised
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incidence rate for colon and small bowel carcinoma was significantly increased, the
values being 11.8 and 3.9 respectively (Kyllönen et al. 2000b).
PTLDs are lymphoid tumours which can involve the GI tract in up to 10% of transplant
recipients and usually occur early after transplantation (Helderman and Goral 2002). 1%
of kidney transplantation patients develop PTLD (American Society of Transplantation
2004). It is usually a B cell lymphoproliferative process, the malignancy of which varies
from a benign polyclonal process that can vanish after immunosuppressive therapy to a
highly malignant monoclonal lymphoma that is resistant to all treatments (Fishman and
Rubin 1998) The incidence depends on the organ transplanted, immunosuppression used
and possible EBV and CMV infections (Muti et al. 2002). 90% of PTLDs are EBV
positive (Gottschalk et al. 2005). Pediatric recipients have a 4-times higher risk to
develop PTLD than adults, probably because they are often primarily EBV seronegative
and receive a transplant from a seropositive donor (Schroff and Rees 2004). Also low
grade gastric mucosa associated lymphoid tissue lymphomas (MALT lymphomas)
associated with H.pylori infections have been documented in transplantation patients (Hsi
et al. 2000, Aull et al. 2003).
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AIMS OF THE STUDY
1. To examine the frequency and possible risk factors for post transplantation GI
complications in Finnish kidney transplantation patients
2. To determine the role of H. pylori infection in upper GI complications in kidney
transplantation patients and to find out the role of immunosuppressive medication
in the course of H. pylori infection
3. To examine the characteristics of gastroduodenal CMV infection in kidney
transplantation patients. To see how often the presence of CMV can be assessed
in the gastroduodenal mucosa of kidney transplantation patients and to find out
whether CMV infection can explain a part of the gastroduodenal complications




This study was carried out at the Department of Transplantation and Liver Surgery of
Helsinki University Central Hospital. The study material consists of patients who
received a kidney transplant in 1990-2000 at the Transplantation Unit. The Ethics
committee of Helsinki University Central Hospital has approved all the studies.
1. KIDNEY TRANSPLANTATION PATIENTS
During 1990-2000 1608 adult patients (977 men, 631 women) underwent 1698 kidney
transplantations. 86 of the patients received 2 and 2 patients 3 kidney grafts.  39 (2.3%)
kidney transplants were from living donors. At the time of the transplantation the median
age of the patients was 45.5 years (range 16.1-76.3 years). Before the transplantation all
patients had been on maintenance dialysis, 907 (56%) on hemodialysis (HD) and 701
(44%) on peritoneal dialysis (CAPD). Figure 3 shows the distribution of the causes of
uraemia in these patients. After the transplantation 95% of the patients received CsA and
4% tacrolimus based triple immunosuppression. The doses used were: AZA 2mg/kg/day,
which was lowered to 1mg/kg/day during the first 2 post operative weeks; CsA 5mg/kg
just before the transplant operation and postoperatively 10mg/kg/day, adjusting the dose
with blood levels; tacrolimus 0.2mg/kg/day and lowering these doses during the 2
postoperative weeks, adjusting the dose with blood levels; and MP 1mg/kg/day lowering
the dose to 0.25mg/kg/day during the 2 post operative weeks. Oral MP 3mg/kg/day for 5
days was used for episodes of acute rejection. Steroid resistant rejection episodes were
treated with OKT3 5mg/day or ATG 1.5m/kg/day or plasmapheresis when vascular
rejection had been detected in histology (Kyllönen 2000 a).
Just before the transplantation operation and 12 hours afterwards the patients received
cephamandole 1g or cephuroxime 750mg intravenously for infection prophylaxis, and
small-dose sulphatrimethoprime (trimethoprime 80mg and sulphamethoxazole 400mg)
was used as pneumocystis carinii (pneumocystis jiroveci) prophylaxis twice a day 3 days
a week for the first 3 months after the transplantation.
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Figure 3. Causes of uraemia in study patients
Ranitidine 150mg/day or omeprazole 20mg/day was used at least in the first
postoperative month as ulcer prophylaxis and acetylsalicylic acid (ASA) 50mg-
100mg/day as thrombosis prophylaxis. In the beginning ganciclovir, from the year 1999
on valacyclovir and from the year 2002 on valgancyclovir was used for CMV
prophylaxis in patients with donor positive and recipient negative combinations for 3
months.
The pre transplantation work up included abdominal US screening and further
examination of patients with GI complaints. Cholecystectomy in cases of gallstones and
colon resection for symptomatic diverticular disease were prerequisites for acceptance on
the kidney waiting list.
Table 1 presents the patients in studies I-V.
*congenital anomalies,vesicourethral reflux etc.













2.1. Data collection (studies I-V)
Clinical data of patients at the time they were accepted on the kidney waiting list, data of
the post transplantation period at the hospital and follow up data sent regularly by the
local nephrologists were retrospectively gathered from the original patient records and
from the Finnish Kidney Transplantation Registry. To complete the information,
questionnaires were sent to 428 patients about upper GI complaints, about how they were
treated and examined (study II) and to 783 patients about diagnosed gallstones,
cholecystectomies and possible gallstone complications, such as cholecystitis,
choledocholithiasis,  cholangitis and biliary pancreatitis (study V).
Gastroduodenal ulcers, severe GI infections and perforations, pancreatitis, cholecystitis
and malignancies that were diagnosed by clinical, radiological or endoscopic methods
were considered severe GI complications. Delayed graft function (DGF) was defined as
serum creatinine concentration higher than 500µmol/l throughout the first post transplant
week, or as the need for more than 1 dialysis session in the first week, or as oliguria of
less than 1000ml/24h for more than 2 days (Kyllönen et al. 2000 a).
2.2. Helicobacter pylori analyses (studies II-III)
The IgG and IgA antibodies for H. pylori were measured from the pretransplant and
follow-up samples by an in-house enzyme immunoassay (Kosunen et al. 1997, Oksanen
et al. 1998).  The cut off-titer was 700 for IgG and 70 for IgA. CagA antibodies (Study
III) were determined from pre transplant serum samples from all 155 primary
seropositive patients by a commercial immunoblot method (I.D.Blot H.pylori IgG, DPC,
Los Angeles, CA, USA) according to the instructions of the manufacturer. Positive bands
containing anti-CagA-antibody were estimated visually.
To confirm H. pylori status of the patients in study III, urea breath test was performed on
36 patients using ¹³C labeled urea (Diabact UBT, Uppsala, Sweden) (Graham et al. 1987),
and H. pylori stool antigen test (Premier platinum HpSA, Meridian Bioscience,
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Cincinnati, USA) was performed on 2 of the patients. OEGD including biopsies was
performed on 8 patients. H. pylori confirmation tests were performed on patients who
were not receiving proton pump inhibitors, H2-blockers or antibiotics to avoid false
negative results.
2.3. Cytomegalovirus analyses (study IV)
The CMV serostatus of all the kidney recipients and donors was determined prior to
transplantation and that of 35 of the control patients at the time of OEGD. CMV viraemia
was determined from blood by means of the CMV pp65 antigenemia test (The et al.
1995) using a monoclonal antibody against CMV pp65 antigens (Biotest Pharma,
Frankfurt, Germany), when CMV infection was suspected, i.e. when patients had fever
and/or their serum creatinine value was elevated without rejection. Biopsies from
pathological findings, as well as biopsies from the second portion of the duodenum and
from the antrum and corpus of the stomach, were taken for paraffin sections from the
transplantation patients and controls. In addition to this, 2 biopsies from the second
portion of the duodenum as well as 2 from the antrum of the stomach were taken for
frozen sections. Routine histopathological examination included Haematoxylin and eosin,
Alcian Blue PAS and Giemsa stainings. The histology of all biopsies was re-examined to
score the inflammatory activity from 1 to 3 with the visual analogue scale according to
the Sydney System (Dixon et al. 1996). CMV was demonstrated in frozen sections by
immunoperoxidase staining using a monoclonal antibody against CMV specific antigen
(pp65 matrix protein) (Halme et al. 2003). In studies later on a monoclonal antibody
against the CMV delayed early protein (p52) (Dako A/S Glostrup Denmark), which
detects the viral inclusions well, was used to demonstrate CMV in paraffin sections of the
samples taken from the duodenum and antrum of the patients.
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2.4. Ultrasound examination of the gallbladder and
determination of lipid values (Study V)
Gallbladder US was performed in 2003-2004 to a subgroup of 304 of the 451 kidney
transplantation patients from the Helsinki area still having a functioning graft and
remaining in the follow up at the Division of Nephrology, Helsinki University Hospital.
In addition to this, data on serum lipid values (total serum cholesterol, serum HDL and
serum triclycerides), body mass index (BMI) and the use of statin medication at the time
of transplantation and at the end of the follow up were collected from the patient records.
3. STATISTICAL ANALYSES
The parametric variables were compared using Student’s T test (studies III-V) and
nonparametric variables with Mann-Whitney U test (studies I and II). Fisher’s exact test
(studies I and III) or chi-square test (studies I-V) was used to compare proportions of
patients between 2 groups.
Patient and graft survival in studies I and II was evaluated using the Kaplan Meier Life
Table method and compared with the Log-rank test. Multivariate analysis in study I was
performed with general regression model Statistica (Data analysis software system
version 6 StatSoft. Inc 2003).
The data is expressed as median and range or mean and 95% confidence intervals.
Significance was established at p<0.05.
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RESULTS
1. GENERAL (Study I)
10% (147) of the 1445 kidney transplantation patients had a severe GI complication
during the follow up in a median time of 0.93 years (range 2 days -11 years) after kidney
transplantation. 15 (6%) of the GI complications were fatal. Patients with GI
complications were older than patients without a complication at the time of
transplantation (median 52.8 vs. 44.6 years, p<0.01). Patients with PKD were found to
have GI complications significantly more often than patients with other causes of uraemia
(14% vs. 8%, p<0.05).
75 (51%) of the verified GI complications in 70 patients occurred during the first
postoperative year and the first year GI complication rate was 4.8% in the whole material.
During the first year 60 (4.2%) patients died, 8 (0.6%) due to GI causes. 5-year patient
survival rate in patients with a first year complication was 68% compared to 88% in
patients with a later or no GI complication (p<0.001). Complications had no effect on the
graft survival.  DGF preceded a GI complication during the first year in 47% of the
patients compared to 31% of the patients without a first year GI complication (p<0.05).
The groups did not differ from each other with regards to rejection therapies or CMV
infections.  The 2 biggest groups of GI complications during the first year were
gastroduodenal ulcers (44%) and colon complications (23%), including 2 gastroduodenal
ulcer perforations and 12 perforations of the colon.
2. GASTRODUODENAL ULCER DISEASE (Studies I-IV)
2.1. The occurrence of gastroduodenal ulcers
During the 10-year follow up period 57 patients suffered from gastroduodenal ulcers with
bleeding or perforation in 19 (33%) of them. The ulcers occurred in a median of 0.6 years
(4 days - 11.2 years) after kidney transplantation. H.pylori infection was found in
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gastroduodenal biopsies from 21% of the ulcer patients and CMV was detected from 7%
of ulcer patients (Study I).
2.2. Helicobacter pylori (Studies II and III)
H. pylori seropositivity was found in 31% of a subgroup of 500 patients and the
seropositivity increased with age. There was no difference in patient or graft survival
between the seropositive and seronegative patient groups. During the first 3 months
gastroduodenal ulcer was diagnosed in 1 seropositive and 5 seronegative patients.  3 of
the ulcers were bleeding (Study II). In 4 patients with ulcers rejection therapy had been
given before the detection of the ulcer and 1 of the seronegative patients had a
concomitant CMV viraemia. Overall there were more ulcers in the H.pylori seropositive
patient group than in the seronegative group (6% vs. 3%, N.S.).
92 of the 93 H.pylori seropositive patients had elevated IgG antibody titers, 73 had
elevated IgA antibody titers, and in 1 patient only IgA titer was elevated. CagA
antibodies were found in 83 (89%) primarily seropositive patients. The median decline in
IgG in the seropositive patients who had not received eradication therapy was from 3400
to 2000 (p<0.01) and the decline in median IgA titer from 170 to 110 (N.S.) during the
median 6.8 year follow up. There was 1 patient with only IgA elevated the titer being
110. The IgA level remained unchanged during the follow-up, but the urea breath test
was negative.
Spontaneous seroreversion of H.pylori, confirmed by 2 different tests occurred in 27
(29%) of the seropositive patients. All spontaneously eradicated patients received
immunosuppressive treatment at least for 4 years. 22% of these patients received
rejection treatment during the first 3 postoperative months compared to 15% of the other
primarily seropositive patients. 8 of the spontaneously seroreverted patients had had a
major infection that needed hospital care and intravenous antibiotics, while 11 of the
remaining patients had only had a minor infection that needed short courses of antibiotics
perorally. Because of the known interaction with CsA, none of these patients were treated
with clarithromycin.
Table 1. Patients and main results of studies I-V
Study      Number of patients (transplantations)                 Characteristics                                      Main results
I                          1445 (1515)                   Consecutive adult kidney transplantation               147 (10%) GI complications occur, 75 (51%)
                                                                      patients transplanted  in 1990-1999                         during the first post transplantation year
                                                                                                                                                     High age, DGF and polycystic kidney disease
                                                                                                                                                       are risk factors for GI complications
                                                                                                                                                     Gastroduodenal ulcers and colon complications
                                            are the  biggest complication subgroups
   II                                500                           Consecutive adult kidney transplantation              H.pylori seroprevalence is 31%
                                                                       patients transplanted in 1991-1994                      H. pylori  has no influence on patient or
                                                                                                                                                        graft survival
  III                             93+88 H.pylori seropositive and seronegative                 Spontaneous eradication of H. pylori occur in
                                                                       patients from study II                                               27 (29%) of patients *
  IV                             46+43                          Kidney transplantation patients transplanted         CMV positive cells are found in the
                                                                       in 1993-2003 and dyspeptic immuno-                      gastroduodenal mucosa of 34 (74%) kidney
                                                                       competent controls                               transplantation patients and 17 (40%) controls
           (p< 0.01)
   V                         1608 (1698)                    Consecutive adult kidney transplantation               196 (12%) patients are diagnosed to have
                                                                       patients transplanted in 1990-2000                           gallstones post transplant despite pre
                                                                                                                                                         transplant screening
                                                                             Gallstone complications are found in 30 (15%)
                                                                   of the patients
* IgG decreased more than 70% or was less than 2000
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2.3. CMV findings in the gastroduodenal mucosa (Study IV)
10 (22%) of the 46 transplantation patients studied (9 < 1 year and 1 > 1 year after
transplantation) had macroscopical erosions with positive CMV pp65 or p52 findings in
the gastric or duodenal mucosa. None of these patients had H. pylori in their biopsies but
5 (50%) revealed inclusions in the CMV p52 analysis. 1 H. pylori negative transplant
patient with a positive CMV finding in the duodenal mucosa had a pyloric ulcer. Table 2
shows the findings of CMV pp65 or p52 in the gastric and duodenal mucosa.  The
histopathological findings in CMV positive samples were not specific but varied a lot and
in general, they were scarce. There were, however, significantly increased amounts of
inflammatory changes in the duodenal mucosa in CMV positive cases. In weakly positive
cases histological changes were, if detected at all, mild and focal. Sometimes p52
immunostaining helped to find the inflammatory focus.
Table 2. CMV findings in the gastroduodenal mucosa of kidney transplantation patients and
controls using a monoclonal antibody against the CMV pp65 antigens in frozen sections and a
monoclonal antitibody against the CMV p52 antigens in paraffin sections. Positive cells / high
power visual field was used as criterion of quantity in CMVpp65 test and inclusions found in
CMVp52 test.
                                           Kidney transplantation patients                                   Controls
All < 1 year after > 1 year after
transplantation         transplantation
n = 46           n = 27                      n = 19                  n = 43
Number of positive CMV pp65 or CMV p52 findings
− Antrum:                        14/46 (30%)      9/27 (33%)        5/19 (26%)          4/43 (9%)1
− Duodenum:                  32/46 (70%)     17/27 (63%)     15/19 (79%)         15/43 (35%)2
− Antrum or duodenum   34/46 (74%)     19/27 (70%) 15/19 (79%)         17/43 (40%)2
1 All kidney transplant patients vs. controls, p < 0.05
2 All kidney transplant patients vs. controls, p < 0.01
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3.GALLSTONE DISEASE AND BILIARY COMPLICATIONS
(Study V)
Cholecystectomy because of gallstones had been performed on 71 (4%) of the 1608
patients before acceptance on the kidney transplantation waiting list. In a cross sectional
study after a median 7.4-year follow up post transplantation an additional 196 (13%)
patients (56% men) were diagnosed to have gallstones. In 165 (84%) of the patients the
gallstones were not found before the transplantations, i.e. they were presumed to have
developed after the transplantation.
After kidney transplantation 30 (15%, 70% of these men) patients with present or
previous gallstones developed a biliary complication. Acalculous cholecystitis occurred
in 4 patients. There was 1 fatal case of cholecystitis due to gallstones. 3 non-fatal
gallbladder perforations, 1 without gallstones, were found. 17 of the patients with biliary
complications required urgent operations.
In a subgroup of 304 (176, 58% of them men) kidney transplantation patients US
screening of the gallbladder was performed after a median 7-year follow up.  In this
group 245 (81%) had no gallstones in the US, 31 (10%) patients had gallstones, and in 28
(9%) patients cholecystectomy had been performed earlier.  Gallstones developed in 28
(10%) patients after transplantation.
Patients with a history of gallstone disease at the time of transplantation were
significantly older than patients without pre transplant gallstone disease (52.3 vs. 44.2
years, p<0.01). Patients with gallstones after transplantation had gained most weight
during the follow up. The increase in BMI was +2.0 in this group compared to +1.1 in
patients without gallstones and +0.9 in patients with a history of pre transplant gallstones
or cholecystectomy (N.S.) Lipid values did not differ between the groups. In the whole
material 95% had CsA as the main immunosuppressive medication and in this subgroup
CsA was the main immunosuppressive medication in all but one of the patients.
4. PANCREATITIS (Study I)
There were 13 cases of pancreatitis in a median 0.9 years (range 4 days - 6.2 years) after
the transplantation. 3 of them were fatal.  2 of the fatal pancreatitis occurred during the
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first postoperative year. Alcohol was the cause of 3 pancreatitis and gallstone disease of
1. In the others no specific aetiology in addition to immunosuppressive drugs could be
found.
5. APPENDICITIS (Study I)
4 patients were diagnosed with appendicitis during the follow up. Of these 2 (50%) were
perforated. Median time from the transplantation to the diagnosis was 0.7 years (range
109 days - 1.2 years).
6. COMPLICATIONS OF THE COLON (Study I)
Colon complications are presented in table 3.  Half of the 16 colon perforations were
caused by diverticulitis. The other colon perforations were caused by ishaemic colitis in
2, pseudo-obstruction in 2 and iatrogenic rectum perforation in 1 patient. In 3 patients no
underlying cause of perforation could be found. 5 (31%) of the 16 colon perforations
were fatal and 4 of them occurred during the first post transplantation year. High age and
PKD were risk factors for colon complications. Patients with PKD as the cause of
terminal uraemia had a higher incidence of diverticulitis than other patient groups
(p<0.01).
Table 3. Complications of the colon in 1515 kidney transplantations of 1445 patients
Complication n=31 Median time after transplantation
(range)
Diverticulitis with perforation 8 1.7 months (4 days- 2.4 years)
Diverticulitis without perforation 12 19 months  (2 days- 7.1 years)
Colitis with perforation 2 1.4 months (4 days-2.6 months)
Colitis without perforation 3 14.4 months (1.2 months- 4 years)
Other colon perforations 6 4.4 months (6 days-5.5 years)
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7. GASTROINTESTINAL MALIGNANCIES (Study I)
13 (0.9%) of the patients developed a GI malignancy during the follow up, 2 of them
during the first post operative year (table 4):  A lymphoma of the jejunum developed to a
male patient 7 months after the transplantation, and 1 female patient had a small sigmoid
cancer (carcinoma in adenoma) 4.6 months after the transplantation. Median time to the
development of GI malignancy was 3.3 years (range 138 days - 10.8 years) after kidney
transplantation.
Summary of the results are presented in table 1.
Table 4. Gastrointestinal malignancies in 1515 kidney transplantations of 1445 patients
Malignancy                                  n=13                           Years after transplantation
                                                                                                  median (range)
Pancreas cancer                             2                                        4.5 (2.4-6.6)
Gastric cancer                                 3                                        2.1 (1.5- 5.1)
Carcinoid tumours                           2                                        4.3 (3.3- 5.3)
Lymphoma                                      1                                              0.59
Cholangio cancer                            1                                               8.1
Colon cancer                                   4                                        2.9 (0.39-10.8)
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DISCUSSION
In this patient material of 1515 kidney transplantations during 1990-1999, which was
screened before transplantation according to the recommendations of EBPG, the
occurrence of serious GI complications was low as compared to earlier studies  (10% vs.
8%-37%)  (Meyers et al. 1978, Bardaxoglou et al. 1993, Benoit et al. 1993). 51% of all
the GI complications and also more than half of the gastroduodenal ulcers and colon
complications in this study were seen during the first post transplant year. This is
probably due to the fact that high doses of immunosuppressive medication must be used
during this early period.
Nowadays, when effective ulcer prophylaxis is used, the frequency of gastroduodenal
ulcers has diminished in the general population as well as after kidney transplantation
(Ohmann et al. 2005, Ponticelli and Passerini 2005, Smith and Stabile 2005). This can
also be seen in the present study that includes only 4% of gastroduodenal ulcers. The
figure is comparable with an earlier study consisting of patients from the 1980’s and
1990’s (Troppmann  et al. 1995).
In study II the incidence of H. pylori seropositivity was 31%.The median age of the
seropositive patients was significantly higher compared to that of the seronegative ones.
These figures did not differ from another series in which the age-dependent occurence of
H. pylori infection was described in a general Finnish population or from other reports of
kidney transplantation patients (Davenport et al. 1991, Gladziwa et al. 1993, Kosunen et
al 1997, Özgur et al. 1997). The number of new H. pylori infections decreases in
developed countries, and consequently, the prevalence of the infection is higher in older
age groups (Talley et al. 1993, Sipponen et al. 1996). H. pylori infection has negligible
influence on the outcome of patients having undergone kidney transplantation. The
frequency of gastroduodenal ulcers or ulcer bleedings within the first 3 post
transplantation months did not increase among the H.pylori positive recipient group in
study II. This is in accordance with an earlier finding that H. pylori infection does not
account for the development of gastroduodenal ulcerative lesions in kidney allograft
patients (Hruby et al. 1997). Furthermore, spontaneous eradication of H. pylori occurred
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in 29% originally H. pylori seropositive kidney transplantation patients in study III after a
median 6.8 year follow up, while in the general Finnish population only 4% of H.pylori
seropositive patients have been found to serorevert (Kosunen et al. 1997). High degree of
spontaneous seroreversion of H.pylori has also been reported in heart and liver
transplantation patients (Dummer et al. 1995, Rudi et al. 1997). Low H.pylori IgG levels
at the time of transplantation, long antibiotic treatment during the follow up and rejection
treatments have been suggested to contribute to seroreversion (Dummer et al. 1995, Rudi
et al. 1997). In addition to this, long-standing immunosuppression may be an important
factor causing spontaneous eradication of H. pylori with reduced immune response to an
ongoing mucosal H.pylori infection. This theory is, however, not supported by the
findings that EBV titers have remained at the pre transplantation level while H.pylori
antibodies have declined after the transplantation in heart transplantation patients
(Dummer et al. 1995) and pneumococcal vaccination has resulted in antibody generation
in kidney transplantation recipients (Arnold et al. 1985).
Other aetiologies than H.pylori for gastroduodenal ulcers are more probable in
transplantation patients.  According to the present data contributing factors could be low-
dose ASA, preceding rejection therapy with high-dose corticosteroids and preceding
CMV infection. Recently, the risk of corticosteroids causing ulcer was shown to increase
only in those who concurrently received non-steroidal anti-inflammatory drugs (Weil et
al. 2000).  CMV, often activated by rejection therapy, causes also ulcerations in the
gastroduodenal mucosa (Goodgame 1993, Halme et al. 1998). Based on these findings,
the screening of H. pylori is not necessary before kidney transplantation.
In study IV, as well as in other studies, CMV was found in the gastroduodenal mucosa of
transplantation patients (Hackman et al. 1994, Shrestra et al. 1996, Muir et al. 1998,
Kaplan et al. 1999).  Also other immunocompromised patients, especially HIV patients,
have plenty of symptomatic GI CMV infections, predominantly colitis (Schwartz and
Wilcox 1992, Baden and Maguire 2001). Interestingly CMV infected cells could also be
found in the gastroduodenal mucosa in 40% of the control patients. There are reports of
gastric or duodenal CMV infection also in immunocompetent patients (Cheung and Ng
1993, Novak et al. 1999, Maionara et al. 2003), though the relevance of this finding
remains obscure. There are different methods to detect CMV infection of the
gastroduodenal mucosa such as demonstration of early and late antigens, PCR
42
techniques, in situ DNA hybridisation and viral cultures (Hackman et al 1994, Muir et al
1998, Ljungman et al 2002). Study IV demonstrates that CMV pp65 and CMV p52
antigens are complementary to each other. According to the present study, as well as to
an earlier study (Maionara et al 2003), demonstration of CMV p52 antigens proved useful
in identifying inclusions and focal inflammatory areas in the gastroduodenal mucosa that
had been overlooked in haematoxylin and eosin stained sections. Furthermore, if a kidney
transplant patient has duodenitis, CMV infection should be strongly suspected, which
another recent study also suggested (Telkes et al 2004). The possibility of CMV infection
should also be searched in kidney transplantation patients with erosions in their
gastroduodenal mucosa.
The prevalence of gallstone disease in solid organ transplantation candidates does not
significantly differ from that of the general population. In studies about kidney or kidney
and pancreas transplantation patients the prevalence has varied between 7%-17%
(Graham et al. 1995b, Greenstein et al. 1997, Moray et al. 2003, Kao et al. 2003). The
result of study V is in accordance with these observations. In the present study 95% of all
the patients used CsA and practically all patients who developed gallstones after
transplantation had CsA as the main immunosuppressive medication. The use of CsA has
been associated with the formation of gallstones probably due to cholestasis and reduced
bile flow (Helderman and Goral 2002). In the general population the rate of serious
complications of gallstone disease is 1%-2% per year (Friedman 1993) In study V, as
shown in other studies, the risk of gallstone complications in transplantation patients
seems to be higher and the progression of symptoms more rapid (Kao et al. 2003, Sianesi
et al. 2005). Because of  immunosuppressive therapy the complications of gallstone
disease can be more severe and the diagnosis delayed in transplantation patients. This
emphasizes the importance of screening and treating also asymptomatic gallstones.
13 (0.9%) of the kidney transplantation patients in study I suffered from acute
pancreatitis. This is in accordance with 0.8%-11% reported in the literature (Frick et al.
1987, Fernandez-Cruz et al. 1989, Slakey et al. 1997, Adani and  Baccarani 2005).
Pancreatitis is a severe complication of kidney transplantation with high mortality. In the
present study the mortality was 23%. No specific aetiology could be found in 9 of the 13
pancreatitis. Moreover, most of the pancreatitis occurred early after the transplantation
when the doses of immunosuppressive medication and the risk of opportunistic infections
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such as CMV are at highest. Viral infections and immunosuppressive medication are
suggested as aetiological factors in post tranplantation pancreatitis (Fernandez-Cruz et al.
1989, Sinha et al. 2003).
The occurrence of colon perforations was 1%, which is comparable with the earlier
studies of kidney transplantation patients varying from 1%-2% (Church et al. 1986,
Stelzner et al. 1997). Colon perforations proved to be very serious: 31% of the
perforations were fatal.  Most of the fatal perforations occurred during the first year after
the transplantation. The diagnosis of colon perforations was often delayed because
immunosuppressive drugs masked symptoms and affected the patients’ responses to the
septic condition.  In this study, as well as in earlier reports, patients with PKD had
significantly more often diverticulitis than patients with other causes of uraemia. (Scheff
et al. 1980, Dominquez Fernandez et al. 1998, Andreoni et al. 1999). According to these
findings the examination of the colon before transplantation is recommended.
Permanent immunosuppressive medication predisposes kidney transplantation patients to
malignancies. Though most of these cancers are of cutaneous origin, the risk of colon
cancer also rises (London et al. 1995, Bustami et al. 2004). It is important to screen pre-
existing cancers before and after transplantation, as recommended by the EBPG expert
group on renal transplantation (EBPG 2000, EBPG 2002). 2 of the malignancies in the
present study were diagnosed during the first postoperative year; the PTLD lymphoma,
first diagnosed as a MALT lymphoma, could probably be explained by high-dose
immunosuppressive medication early after transplantation, and the small sigmoid
carcinoma (carcinoma in adenoma) was probably missed in pre transplantation
examinations. In study II 2 H.pylori seropositive patients and no seronegative ones
suffered from gastroduodenal malignancies. There has been a lot of discussion of the role
of H. pylori in the genesis of gastric carcinoma, and in 1994 H.pylori was classified as a
group I carcinogen by the International Agency for Research on Cancer it being 1 of the
co-factors involved in the development of neoplastic transformation of gastric mucosa
(IARC 1994, Parsonnet et al. 1991, Kokkola et al. 1996). This justifies the treatment of
known H.pylori infection before transplantation.
Kidney transplantation patients suffer from severe GI complications especially during the
first post transplantation year but also later. Besides ordinary aetiologies also more rare
aetiologies of GI complications should be suspected in this patient group.
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CONCLUSIONS
On the basis of the present study the following conclusions can be drawn:
1. The frequency of severe GI complications in Finnish kidney transplantation patients
is 10%. 51% of these complications occur during the first post transplant year.
Especially serious complications in this patient group are GI perforations. High age,
DGF and PKD increase the risk of GI complications.
2. H. pylori infection is common among kidney transplant patients, but it does not
increase the risk of postoperative gastroduodenal complications nor does it affect
graft or patient survival. Spontaneous eradication of H. pylori that is based on
significant decrease of the IgG antibody titer is common occurring in 29% of
kidney transplantation patients. Long-standing immunosuppressive medication may
be the cause of spontaneous seroreversion.
3. CMV infected cells and inclusions are found in the gastroduodenal mucosa in 74%
of kidney transplant patients. In kidney transplant patients CMV causes ulcerative
gastroduodenitis, and this might explain some gastroduodenal symptoms.
 4.    Gallstone disease occurs in 12% of patients after kidney transplantation, which does
not differ from a normal population. The complications of gallstone disease can be
severe in kidney transplantation patients.
These results of kidney transplantation patients demonstrate the importance of meticulous
pre transplant screening and post transplant follow up and treatment of GI disorders in at
least elderly patients, patients with PKD and patients with DGF. Diagnosed H.pylori
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